Latest news about Novyra Pharmachem
Novyra Pharmachem
9.16
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M-14.15%
6M-44.65%
1Y0.00%
5Y0.00%
More news about Novyra Pharmachem
25Apr 26
Novyra Pharmachem Limited Further Reschedules Board Meeting to April 29, 2026
Novyra Pharmachem Limited has announced another revision to its board meeting schedule, postponing the meeting from April 25 to April 29, 2026. This marks the second rescheduling for the consideration of Q4FY26 audited financial results and auditor's report. The company has communicated this change to BSE Limited under Regulation 29 of SEBI regulations.
11Apr 26
Novyra Pharmachem Limited Submits Q4FY26 Dematerialization Certificate
Novyra Pharmachem Limited has filed its mandatory certificate under SEBI Regulation 74(5) for Q4FY26, confirming proper dematerialization process compliance through registrar S.K. Infosolutions Pvt. Ltd. The company continues with its scheduled board meeting on April 18, 2026, to consider audited financial results while maintaining trading window restrictions until 48 hours after results declaration.
20Mar 26
Novyra Pharmachem Limited Conducts Independent Directors Meeting on March 20, 2026
Novyra Pharmachem Limited held its independent directors meeting on March 20, 2026, lasting from 01.00 P.M. to 06.45 P.M. at its Surat office. The meeting reviewed non-independent directors' performance, assessed the chairperson's effectiveness, and evaluated information flow between management and the board, fulfilling SEBI LODR regulatory requirements for Financial Year 2025-26.
06Feb 26
Novyra Pharmachem Limited Appoints Anilkumar Mohanbhai Amreliya as Additional Executive Director
Novyra Pharmachem Limited appointed Anilkumar Mohanbhai Amreliya as Additional Director (Executive Director) effective February 6, 2026, following board approval. The new director brings over 25 years of sales and marketing experience and will serve until the next Annual General Meeting. The company has confirmed full regulatory compliance with SEBI requirements for the appointment.
26Jan 26
Novyra Pharmachem Limited Reports Q3 FY26 Net Loss of ₹1.15 Lakhs
Novyra Pharmachem Limited (formerly Bansisons Tea Industries) reported a net loss of ₹1.15 lakhs for Q3 FY26 ended December 31, 2025, compared to ₹0.88 lakhs loss in Q3 FY25. The company generated no operational revenue during the quarter, with total expenses of ₹1.15 lakhs. For the nine-month period, the net loss increased to ₹1.82 lakhs from ₹1.34 lakhs in the previous year, despite other income of ₹6.31 lakhs. The Board approved these results on January 26, 2026.
30Dec 25
Bansisons Tea Industries Shareholders Approve Name Change to Novyra Pharmachem
Bansisons Tea Industries has successfully completed its postal ballot process with unanimous shareholder approval for its transformation into Novyra Pharmachem Limited. All three resolutions received 100% approval from 35 participating shareholders representing 805,000 votes, enabling the company's strategic pivot from tea operations to pharmaceutical manufacturing and research activities.
24Dec 25
Bansisons Tea Industries Gets New CIN After Gujarat Office Relocation Approval
Bansisons Tea Industries Limited has successfully completed its registered office relocation from West Bengal to Gujarat with a new CIN L15520GJ1987PLC171085 effective December 24, 2025. The company received initial approval from Regional Director Kolkata on November 28, 2025, and final CIN change approval from MCA on December 24, 2025, with proper disclosure made to BSE under SEBI regulations.
22Dec 25
Bansisons Tea Industries Clarifies Audit Compliance for FY2020-21 Financial Results
Bansisons Tea Industries Limited clarified to BSE that its statutory auditors issued an unmodified audit opinion for FY2020-21 with no qualifications, making the Declaration on Impact of Audit Qualifications non-applicable. The company achieved a turnaround with net profit of ₹7.89 lakhs versus previous year's loss of ₹1.79 lakhs, while maintaining revenue of ₹15.00 lakhs. The non-submission was described as inadvertent, and the company resubmitted financial results to ensure compliance.
16Dec 25
Bansisons Tea Industries Reports 89% Decline in Net Profit for FY22
Bansisons Tea Industries Limited reported a sharp 89% decline in net profit to ₹338.46 for FY22 compared to ₹7,886.52 in FY21. While revenue remained stable at ₹150.00, total expenses surged 68% to ₹185.36, primarily due to higher employee costs and operational expenses. The company received an unmodified audit opinion and clarified compliance matters with BSE regarding audit report submissions.
22Nov 25
Bansisons Tea Industries' Independent Director Mamy Ghosh Resigns, Citing Pre-occupation
Mrs. Mamy Ghosh has resigned from her position as Independent Director of Bansisons Tea Industries Limited, effective November 19, 2025, citing pre-occupation. The company has initiated necessary procedures to process the resignation. This change will impact the board's composition, and the company may begin the process of appointing a new Independent Director.
Industry Peers
Tata Consumer Products
CCL Products
Andrew Yule & Company
Goodricke Group
McLeod Russel
The Peria Karamalai Tea & Produce
Jay Shree Tea & Industries
Gillanders Arbuthnot
Neelamalai Agro Industries
United Nilgiri Tea
986.30
(-0.80%)
1,039.50
(-0.35%)
26.85
(-4.41%)
229.00
(-2.18%)
44.84
(-5.00%)
1,010.00
(+2.21%)
87.92
(-1.82%)
103.00
(-1.82%)
3,468.80
(0.0%)
431.00
(+0.70%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
